Literature DB >> 28187379

Novel doxorubicin loaded PEGylated cuprous telluride nanocrystals for combined photothermal-chemo cancer treatment.

Xianwen Wang1, Yan Ma2, Huajian Chen1, Xiaoyi Wu3, Haisheng Qian1, Xianzhu Yang1, Zhengbao Zha4.   

Abstract

Recently, combined photothermal-chemo therapy has attracted great attention due to its enhanced anti-tumor efficiency via synergistic effects. Herein, PEGylated cuprous telluride nanocrystals (PEGylated Cu2Te NCs) were developed as novel drug nanocarriers for combined photothermal-chemo treatment of cancer cells. PEGylated Cu2Te NCs were fabricated through a simple two-step process, comprised of hot injection and thin-film hydration. The as-prepared PEGylated Cu2Te NCs (average diameter of 5.21±1.05nm) showed a noticeable photothermal conversion efficiency of 33.1% and good capacity to load hydrophobic anti-cancer drug. Due to the protonated amine group at low pH, the doxorubicin (DOX)-loaded PEGylated Cu2Te NCs (PEGylated Cu2Te-DOX NCs) exhibited an acidic pH promoted drug release profile. Moreover, a three-parameter model, which considers the effects of drug-carrier interactions on the initial burst release and the sustained release of drug from micro- and nano-sized carriers, was used to gain insight into how pH and laser irradiation affect drug release from PEGylated Cu2Te-DOX NCs. Based on the results from in vitro cell study, PEGylated Cu2Te-DOX NCs revealed remarkably photothermal-chemo synergistic effect to HeLa cells, attributed to both the PEGylated Cu2Te NCs mediated photothermal ablation and enhanced cellular uptake of the drug. Thus, our results encourage the usage of Cu2Te-DOX drug nanocarriers for enhanced treatment of cancer cells by combined photothermal-chemo therapy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-tumor treatment; Chemotherapy; Cuprous telluride; Drug nanocarriers; Photothermal therapy

Mesh:

Substances:

Year:  2017        PMID: 28187379     DOI: 10.1016/j.colsurfb.2017.02.002

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  7 in total

Review 1.  Inorganic nanomaterials for chemo/photothermal therapy: a promising horizon on effective cancer treatment.

Authors:  Mona Khafaji; Masoud Zamani; Mortaza Golizadeh; Omid Bavi
Journal:  Biophys Rev       Date:  2019-05-17

Review 2.  Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives.

Authors:  Qing-Long Guo; Xing-Liang Dai; Meng-Yuan Yin; Hong-Wei Cheng; Hai-Sheng Qian; Hua Wang; Dao-Ming Zhu; Xian-Wen Wang
Journal:  Mil Med Res       Date:  2022-06-09

3.  Polymer-Based Nanocarriers for Co-Delivery and Combination of Diverse Therapies against Cancers.

Authors:  Guowen Yan; Aihua Li; Aitang Zhang; Yong Sun; Jingquan Liu
Journal:  Nanomaterials (Basel)       Date:  2018-02-03       Impact factor: 5.076

4.  Fabrication of Poly(ethylene glycol) Capsules via Emulsion Templating Method for Targeted Drug Delivery.

Authors:  Shuang Yang; Feng Ding; Zhiliang Gao; Jianman Guo; Jiwei Cui; Peiyu Zhang
Journal:  Polymers (Basel)       Date:  2020-05-14       Impact factor: 4.329

Review 5.  A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies.

Authors:  Ying Gao; Dongruo Gao; Jie Shen; Qiwen Wang
Journal:  Front Chem       Date:  2020-11-24       Impact factor: 5.221

6.  NIR-guided dendritic nanoplatform for improving antitumor efficacy by combining chemo-phototherapy.

Authors:  Ruifen Ge; Jie Cao; Jinnan Chi; Shangcong Han; Yan Liang; Lisa Xu; Mingtao Liang; Yong Sun
Journal:  Int J Nanomedicine       Date:  2019-07-08

7.  Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties.

Authors:  Brice Martin; Johanne Seguin; Maxime Annereau; Thomas Fleury; René Lai-Kuen; Giovanni Neri; Anita Lam; Marcel Bally; Nathalie Mignet; Yohann Corvis
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.